POZ Community Forums

Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: Jim Allen on March 31, 2022, 12:55:41 pm

Title: Cabenuva Now Approved for Teens
Post by: Jim Allen on March 31, 2022, 12:55:41 pm
Poz.com in full:

In Short:

The Food and Drug Administration (FDA) has extended the indication for Cabenuva (injectable cabotegravir plus rilpivirine) to include adolescents ages 12 and up. This will enable eligible young people living with HIV to take antiretroviral therapy just six or 12 times per year.

Daily antiretroviral pills are highly effective, but some people find long-acting injections more convenient, which could lead to better adherence. This could be especially important for adolescents, as some studies have found that this group struggles with adherence.

It is indicated as maintenance therapy for adults and adolescents weighing at least 77 pounds (35 kilograms) who have achieved viral suppression (a viral load below 50 copies) on daily oral antiretroviral therapy and who have no history of treatment failure and no known or suspected resistance to either drug.